Opinion|Videos|June 6, 2025
Addressing Critical Gaps in the Management of NSCLC and the Importance of the Next Wave of Treatment Advances
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how emerging research in non–small cell lung cancer (NSCLC) is focused on determining the most effective neoadjuvant/adjuvant approaches combining chemotherapy with immunotherapy, addressing tumor heterogeneity through potential combinations of targeted therapies, and investigating mechanisms of immunotherapy nonresponse to improve patient outcomes.
Advertisement
Episodes in this series
Current Research Challenges
- Early-stage NSCLC:
- Multiple FDA approvals for neoadjuvant/adjuvant chemoimmunotherapy; awaiting mature data to establish optimal approach
- Tumor heterogeneity: Multiple targetable mutations often present; no current data on combining targeted therapies
- Immunotherapy nonresponders: Research needed to understand mechanisms of nonresponse and identify additional targets
- Focus on minimizing toxicity exposure when benefit cannot be guaranteed
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
3
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
4
PCV20 Demonstrates Real-World Effectiveness Against Pneumonia in Older Adults
5
